MINIject® is iSTAR Medical’s innovative minimally-invasive glaucoma surgery (MIGS) device for patients with open-angle glaucoma.


MINIject® is currently the only commercially available MIGS implant targeting the supraciliary space, which is shown to deliver safe, meaningful and sustained control of intraocular pressure (IOP).

play the video
“Over the next five years, MIGS will drive the glaucoma device market” Market Scope, “2021 Glaucoma Surgical Device Market Report”, July 2021

Designed to be a leading MIGS device


MINIject® is designed to significantly reduce IOP by enhancing natural outflow from the anterior chamber to the supraciliary space. Implantation is predictable in a single-step procedure using a deployment wheel.







MINIject and STAR material
STAR material

STAR Material

MINIject®’s distinctive, soft and flexible porous structure delivers multiple benefits:

  • iSTAR Medical’s proprietary STAR® material exhibits outstanding anti-fibrotic and anti-inflammatory properties 1
  • Porous implant enables a natural flow of aqueous humor, helping reduce fibrosis, minimise scarring and increase durability 1
  • Conforms to the eye’s anatomy and bio-integrates with surrounding tissue to sustain long-term drainage efficacy 1,2
MINIject implanted in suprachoroidal space

Swift and intuitive access through the supraciliary space

  • A safe, minimally-invasive, ab-interno procedure 3
  • Spares the conjunctiva and avoids bleb formation
  • Implanted far away from the cornea (only 0.5mm in the anterior chamber) 3
  • Minimises post-operative patient management and recovery time 3

Key benefits


MINIject® is currently the only commercially available MIGS device that enhances natural flow in the supraciliary space with bio-integration, for safe, meaningful and sustained control of IOP.



MINIject on a finger

Clinical Data

Clinical data of MINIject® in standalone trials at two-year follow-up has shown: 3

  • 35-40% mean IOP reduction after two years
  • Meaningful IOP reduction to <15mmHg in most patients
  • Approximately half of patients drop-free
  • Low rate of complications
  • No needling or bleb-management required
  • Favourable endothelial cell density safety at two years
MINIject delivery system

Instructions for use (IFU)

Current IFU

MINIject (FG1004)

Version 13, 2022-09-16

English / German / Spanish / French / Italian / Dutch 

Version 13, 2022-09-16

Swedish / Norwegian / Finnish / Portuguese 

IFU Archive

MINIject (FG1004) 

Version 12, 2022-08-18

English / German / Spanish / French / Italian / Dutch 

Version 12, 2022-08-18

Swedish / Norwegian

Version 11, 2021-10-04 

English / German / Spanish / French / Italian / Dutch 

Version 10, 2021-07-14

English / German 



Please contact us at [email protected] if you require further information.


MINIject® is only available for sale in the European Union, the UK, Norway, Iceland, Switzerland and Australia.

MINIject® safety and efficacy results are currently sustained out to 3 years, as presented by Dr Ike Ahmed at WGC 2021.

1 Grierson I, Minckler D, Rippy MK et al. “A novel suprachoroidal microinvasive glaucoma implant: in vivo biocompatibility and biointegration.” BMC biomed eng 2, 10 (2020).

2 Ultrasound Biomicroscopy (UBM) images on file

3 Data on file and presented by CEO Michel Vanbrabant at Ophthalmology Innovation Summits (OIS) in 2021. Denis P, Hirneiß C, Durr GM, et al. “Two-year outcomes of the MINIject drainage system for uncontrolled glaucoma from the STAR-I first-in-human trial”. Br J Ophthalmol 2020;0:1–6

scroll to up
Sign up to receive company news alerts